Sarepta’s Duchenne gene therapy fails to meet primary endpoint in pivotal trial
![](http://iamd.in/wp-content/uploads/2024/02/Sarepta-Therapeutics-768x403.jpg)
Sarepta Therapeutics said Monday afternoon that its gene therapy for Duchenne muscular dystrophy failed to improve muscle function compared to a placebo in a large clinical trial — likely a major disappointment for patients and doctors who have been desperately…